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In-vivo resistance of Plasmodium falciparum to chloroquine and 
amodiaquine in South Cameroon and age-related efficacy of 
the drugs
Chloroquine resistance o f  Plasmodium falci­
parum (CRPF) was first observed in Cameroon 
in 1985, in the south-west o f the country, a 
region which is hyperendemic for malaria 
(Sansonetti el aln 1985). Although such resist­
ance has since spread rapidly throughout the
country (Louis el aln 1992; Basco el a l,, 1993),
chloroquine still remains the most widely used 
antimalarial drug. Most of the information 
collected by the local Ministry o f  Health on 
CRPF is biased because it comes from studies 
in schoolchildren, in whom the immune re­
sponse is likely to complement the action of  
drugs, by clearing parasites from the blood 
(Targett, 1992). Studies must also be conduc­
ted among other groups, particularly of chil­
dren aged <  5 years and pregnant women, if  
(1) the public-health problem posed by CRPF  
is to be fully addressed and (2) control mea­
sures and treatment policies are to be effec­
tive. A study to assess how the efficacy of  
chloroquine and amodiaquine varied with the 
age of the subject treated was therefore con­
ducted in Ebolowa, a town with about 35 000 
inhabitants, in South Cameroon, 160 km 
south of Yaounde, The region is characterised 
by an equatorial climate. Although rain foils 
all year round (with an annual total of about 
1700 mm), it is heaviest between September 
and December and between April and June. 
This pattern allows sites suitable for the 
breeding o f anopheline mosquitoes to persist 
throughout each year and transmission of 
Plasmodium spp. is perennial in the region. 
Health services in Ebolowa are provided by 
one state, provincial hospital (Ekombitie Hos­
pital), one missionary hospital (EPC Enongal 
Hospital) and state or missionary health cen­
tres. Oral chloroquine is the current first-line 
treatment for uncomplicated malaria, whereas 
intramuscular or intravenous injections of 
quinine are used for severe malaria. Most
(59.8%) o f the families of the subjects investi­
gated declared that they used drugs for the 
prevention of malaria, most (95%) of these 
using chloroquine. However, only 16% of 
the mothers interviewed gave a dose of 
chloroquine to their children which was large 
enough to be considered effective even against 
non-resistant malaria.
Overall, 250 infants (12-24 months), 120 
young children (36-60 months) and 600 
schoolchildren (5—15 years) were screened for 
malaria by examination o f  Giemsa-stained 
blood smears. The schoolchildren, from one 
district of Ebolowa, were screened in April
1995 and the younger children, from Ebolowa
or its surroundings, were screened monthly 
between September and December 1994. The 
192 children enrolled for further study were 
the asymptomatic subjects who had >  1000 
P. falciparum  parasites/^1 blood but had not 
taken any treatment within 3 days of the initial 
examination. Each enrolled child was given a 
total o f 25 mg chloroquine or amodiaquine/kg 
over 3 days (10, 10 and 5 m g/kg on days 0, 1 
and 2, respectively). Each dose was adminis­
tered as tablets (of 100 mg chloroquine or 
200 mg amodiaquine) under the supervision of 
a team member. The initial aim was to give 
chloroquine to three of every four schoolchil­
dren as they enrolled and to two of every three 
of the younger children (the other children 
receiving amodiaquine). However, as 23 chil­
dren were lost to follow-up, the final 
chloroquine:amodiaquine ratios were slightly 
different. The in-vivo response of the P. falci­
parum parasites in each subject was assessed 
using a slightly modified 7-day test (Bruce- 
Ghwatt, 1986). Thick, Giemsa-stained blood 
smears were prepared from each subject on 
days 3 and 7. Parasitaemias were then esti­
mated by counting the parasites/200 leuco­
cytes (positives) or 1000 leucocytes (negatives)
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Chloroquine and amodiaquine resistance by subject age and by level of resistance on day 7 after initiation o f treatment
Treatment
Ch lo i '0 quine A modia qu in e
Age (years) 1-4 5-15 1-4 5-15
No. of subjects 49 65 35 20
Mean and (s.D.) of ages
(years) 2.2 (2.0) 8.8 (4.2) 2.5 (2.4) 8.4 (4.5)
Mean parasitaemia
(and 95% Cl) on day 0
{parasites/¿¿l blood) 6137(4425-8527) 2306 (1890-2814) 6067 (3879-9251) 3555 (2218-5807)
RESISTANCE (% of subjects)
s 45.8 49.2 85.7 95.0
RI/RII 45.8 50.8 14.3 5.0
RIII 8.4 0 0 0
Cl, Confidence interval.
and assuming that each subject had 8000 leu­
cocytes/ fxl blood. All blood smears were read 
by one microscopist who was unaware of the 
drug used to treat each child.
For the main statistical analysis, the sub­
jects were split into two age-groups: young 
(1-4  years); and old (5-15 years). Differences 
in the frequencies o f  each level o f  resistance 
(S, R I/R II or RIII) with age-group were 
analysed by %2 test. [Those found apara- 
sitaemic on day 7 were considered to be in­
fected with sensitive (S) strains of the 
parasite.] Geometric mean parasitaemias were 
compared by analysis o f variance after log- 
transformation. Values o f P C 0.05 were con­
sidered significant.
The prevalence of infection with CRPF (see 
Table) was high in both age-groups ( >  50%) 
but an RIII response to chloroquine was only 
observed in four children, all of them young. 
O f those given chloroquine, most (32; 69.6%) 
of the young children had positive blood 
smcars on day 3, compared with just 14
(29.6%) o f  the old children (P <  0.0001), and
the mean (and range) of the parasitaemias at 
this time was also higher in the young chil­
dren [963 (537-1729) v. 174 (83-384) para-
site//il]. Although 32 o f  the old children given 
chloroquine had negative blood smears on day
7 (and were therefore considered S responses),
11 (41%) of 27 of them re-tested on day 14 
were then found positive.
The treatment efficacy of amodiaquine on 
day 7 was >  85% in both age-groups (see 
Table) and no RIII responses to this drug 
were observed. Among those given amodi­
aquine, the proportions o f each age-group 
which were smear-negative on day 3 were 
similar [30/35 (85.7%) of the young children 
v, 19/20 (95%) of the old]. Nineteen o f the
old children given amodiaquine were smear- 
negative on day 7; only one o f the 16 o f these 
re-tested on day 14 was then smear-positive.
None of the subjects (including those lost to 
follow-up who were seen later) developed any 
symptoms requiring health care during the 
follow-up period
The overall CRPF prevalence, in children
aged 1-15 years, was 52.8%. T he CRPF in 
the asymptomatic schoolchildren of Ebolowa 
(50.8%) is considerably higher than Mulder 
et al. (1994) found in asymptomatic 
schoolchildren in Edea (31.5%), also located 
in South Cameroon. However, the difference 
may perhaps be the result of excluding those 
with low parasitaemias ( ^  1000 parasites/^1) 
from the present study, as no such threshold 
was applied in Edea.
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The efficacy of antimalarial treatment is 
modified by the immune status of the host 
(Bjorkmann and Phillips-Howard, 1990; Baird 
el al., 1991; Targett, 1992). Premunition de­
velops progressively in young children; rap­
idly in some, less quickly in others, depending 
on the level o f endemicity prevailing in the 
area, Very young children may be considered 
non-immune individuals. Although in-vivo 
drug resistance did not vary with the age o f  
the subjects in the present study, CRPF was 
present in most (65.5%) o f  the 29 subjects 
aged 1-2 years who were given chloroquine, 
and RIII responses were only observed in the 
younger subjects. The old children cleared 
their parasitaemias faster than the young chil­
dren, perhaps reflecting premunition in the 
former.
Given the high CRPF prevalence encoun­
tered in Ebolowa, the continued use o f  
chloroquine as the first-line treatment for 
malarial infections might seem surprising, 
However, chloroquine may remain an effective 
symptomatic treatment in areas where high 
CRPF rates prevail, and its use may still 
greatly reduce the risk of severe malaria devel­
oping (Muller el a l 1996). T he consequences 
of being a chronic carrier o f P. falciparum., 
however, remain unknown and continued use 
of chloroquine may permit the existing RIII 
strains to spread and make the situation more 
serious. Children with highly resistant para­
sites are at an increased risk o f developing 
severe malaria (Brewster and Greenwood, 
1993), The results of re-testing children who 
were apparently infected with sensitive para­
sites 7 days after the 7-day test are interesting 
as they indicate delayed resistance, particu­
larly in the older children. Most studies o f  
drug resistance are carried out in older 
(school-age) children. It seems advisable to 
extend these studies to the target risk groups, 
such as young children. Carrying out in-vivo 
tests among asymptomatic young children or 
infants may be a simple means of studying the 
level of drug resistance o f  P. falciparum  more 
precisely and of anticipating the evolution of  
resistance to drugs among the whole popu­
lation more accurately.
Amodiaquine remains a fairly
treatment of falciparum malaria in children of 
all age groups in South Cameroon (present 
study) and in The Gambia (Muller et al., 
1996). Although amodiaquine is not recom­
mended as a curative treatment by the World 
Health Organization (1990), because of the 
risk o f agranulocytosis (Hatton et aL, 1986) 
and hepatitis (Neftel et a i , 1986), its 
riskrbenefit ratios for prevention and treat­
ment are quite different (Phillips-Howard and 
West, 1990). T o deal with the evolution of  
drug resistance in Central Africa, therapeutic 
policies need to be reassessed and amodi­
aquine needs to be considered as an alternative 
to chloroquine as the first-line treatment.
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